How to Design and Validate a Clinical Flow Cytometry Assay

Area of Science:

• Hematology
• Clinical Immunology
• Laboratory Medicine

Background:

• Multiparametric flow cytometry (MFC) is a cornerstone in diagnosing hematologic malignancies like leukemias and lymphomas.
• Currently, MFC assays are primarily laboratory-developed tests (LDTs) due to a lack of FDA-approved standardized tests.
• This necessitates robust validation and adherence to evolving guidelines for accurate clinical application.

Purpose of the Study:

• To provide a historical context for the current state of MFC assay development.
• To summarize the critical recommendations from the recent Clinical and Laboratory Standards Institute (CLSI) H62 guidelines.
• To offer practical insights and best practices for designing and validating MFC assays based on expert experience.

Main Methods:

• Review of historical developments in flow cytometry for hematologic diagnostics.
• Analysis and synthesis of key recommendations from the CLSI H62 guideline document.
• Compilation of practical considerations and lessons learned from hands-on MFC assay development.

Main Results:

• MFC assays are indispensable for leukemia and lymphoma diagnosis.
• The CLSI H62 guidelines offer the most comprehensive framework for MFC assay design and validation.
• Practical challenges in assay development can be mitigated by following established protocols and expert guidance.

Conclusions:

• Standardization and rigorous validation of MFC assays are critical for reliable patient diagnosis.
• Adherence to CLSI H62 guidelines is essential for developing robust and reproducible flow cytometry tests.
• Expert experience combined with standardized guidelines enhances the quality and clinical utility of MFC assays.